HDAC9 and neoplasm: In addition, givinostat, a class I/II HDAC inhibitor, blocked tumor regression and metastasis when used with DNMTi (azacitidine), anti-CTLA-4 mAb, or anti-PD-1 mAb in an NSCLC model158.